Series A $77.5M Raised

R1 Therapeutics

Your Custom Growth Program
— built by Arden CMO Advisory

Prepared for Leadership Team
Confidential · Not for Distribution
Program In Progress

Your program is already in motion.

I've already started building your custom growth program for R1 Therapeutics. With $77.5M in Series A, your kidney disease pipeline addresses massive unmet need. Here's how we'll attract pharma partners and top talent.

Program at a Glance
$77.5M Series A · Capital to scale GTM
4 High-conviction growth strategies
90 Day sprint to board-ready metrics

Want to see the full program? This brief is just the surface — let's walk through the details together.

Book a Strategy Session →
Customer Analysis

Who We're Targeting

I've scored the market and identified R1 Therapeutics's highest-value segments. Here's why each one is in the program.

Priority #1 Segment

Nephrology KOLs

Key opinion leaders at top academic nephrology centers

Top 50 nephrology centers
Key Performance Signal
10+ pharma renal franchises

Pharma Partners

Large pharma with renal franchises seeking pipeline additions

500+ CKD trial sites

Clinical Investigators

Nephrologists who can serve as principal investigators

NKF + AKF

Patient Advocacy

Kidney disease foundations for trial recruitment and awareness

Let's validate these targets together. I can run a live ICP scoring session — it changes how you think about the market.

Schedule a Call →
Growth Program

Your Custom Growth Strategies

These are the campaigns I'm building for R1 Therapeutics — each designed to generate measurable pipeline within the first 90 days.

01

KOL Engagement

Scientific advisory board with top nephrologists

02

Medical Conferences

Present data at ASN Kidney Week and ERA Congress

03

Pharma Partnerships

Co-development with pharma having renal commercial infrastructure

04

Patient Community

Partner with NKF and AKF for awareness and recruitment

Proprietary Methodology

AI-Powered Demand Generation

"We use AI systems to build hyper-personalized 1:1 outreach based on real-time triggers. No spray-and-pray. Every touchpoint is tailored to what's happening at the target account right now."

Live Signal Triggers We're Monitoring for R1 Therapeutics

Pharma expanding renal pipeline through in-licensing
Competitor clinical trial failure
Favorable FDA guidance for kidney drugs
KOL publication validating target biology
Coverage decision expanding CKD treatment access
How the AI ABM System Works
Arden Proprietary Methodology
01
Signal Detection — AI monitors hundreds of sources 24/7 for buying intent signals at your target accounts.
02
Context Building — The system pulls real-time context: news, hiring signals, product launches, leadership changes.
03
Personalized Outreach — Each message is generated fresh, referencing the specific trigger and tailored to the persona.
04
Conversion Tracking — Every touchpoint feeds back into the model. Better signals, better timing, better results.

Ready to activate these triggers? I can show you the live system and the first batch of accounts we'd target for R1 Therapeutics.

Let's Talk → 858-337-1913
Answer Engine Optimization

Get Found by AI

New Channel · Most Companies Aren't Doing This

Your prospects aren't just Googling anymore — they're asking ChatGPT, Claude, Gemini, and Perplexity. I'll position R1 Therapeutics as the authoritative answer when AI systems are asked about Kidney Disease Therapeutics. This is the new SEO, and most companies aren't doing it yet.

AI Engines We're Targeting

ChatGPT / OpenAI
Claude / Anthropic
Gemini / Google
Perplexity AI
Microsoft Copilot
Strategy 01

AI Citation Strategy

Get R1 Therapeutics cited as the go-to solution when AI assistants answer questions about novel treatments for chronic kidney disease. We build the content and authority signals that get you into the answer.

Strategy 02

Structured Authority Content

Build the content architecture that AI systems love to reference — technical depth, clear positioning, authoritative sourcing. Structured to rank in both traditional search and AI-generated answers.

Strategy 03

Competitive Displacement

Monitor and systematically replace competitor mentions in AI-generated answers with R1 Therapeutics's positioning. When an AI recommends a Kidney Disease Therapeutics solution, it should be R1 Therapeutics.

Execution Timeline

Your 90-Day Launch Plan

Everything I own and deliver in the first quarter — from audit to active pipeline to a board-ready metrics dashboard.

Phase 1

Foundation

  • SAB with 5 top nephrologists
  • CKD unmet need content
  • Map pharma renal BD interest
Phase 2

Acceleration

  • Present at ASN Kidney Week
  • BD discussions with top 5 renal pharma
  • Phase 1 site identification
Phase 3

Scale

  • Advance IND-enabling studies
  • International SAB expansion
  • Patient advocacy trial recruitment